We have developed a novel experimental treatment approach for advanced hepatocellular carcinoma, which consists in the systemic delivery of low and safe levels of 27.12 MHz radiofrequency electromagnetic fields. These radiofrequency electromagnetic fields are amplitude-modulated at specific frequencies, which target the growth of cancer cells and do not affect the growth of normal cells.
The TheraBionic P1 investigational medical device is currently intended for the experimental treatment of advanced hepatocellular carcinoma in patients who have failed or are intolerant to first line and 2nd line therapies. The investigational device is considered low risk and can be administered to patients with severely impaired liver function as exemplified by the fact that some patients with Child Pugh B9 liver function included in the clinical studies have derived significant benefit from the treatment. Given the investigational medical device apparent lack of liver toxicity, it is not expected that use of the TheraBionic P1 device will further impair the patient’s liver function. The TheraBionic investigational device is not FDA approved and is therefore not commercially available. However, if you are considering an experimental treatment with the TheraBionic P1 for your patient, several options are available: